Recently, all three EASIX scores have been associated with the development of severe CRS and ICANS in patients who received C-type lectin-like molecule 1 CAR-T cell immunotherapy for acute myeloid leukemia [33]. This evidence concerns the gene CLEC12A and congenital rubella syndrome.